In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the pump and dump stocks. Pump and dump stocks are typically characterized by high 52-week ...

Noah Berkowitz, the Chief Medical Officer of $ARVN, sold 8,658 shares of the company on 03-18-2025 for an estimated $74,372. We received data on the trade from a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Arvinas, Inc. (ARVN) shares soared 8.8% in the last trading session to close at $9.03. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Amarin Corporation plc AMRN reported a loss of 12 cents per share for the fourth quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 6 cents. The company had reported a ...

Fintel reports that on March 12, 2025, Wedbush downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to Neutral. Analyst Price Forecast Suggests 554.89% Upside As of March 4 ...

Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed initial results from a Phase 3 trial for the protein degrader on Tuesday.

Price Action: ARVN stock is down 52.4% at $8.35 at the last check Tuesday.

Investing.com -- Shares of Arvinas, Inc. (NASDAQ:ARVN) plummeted 41% today following the announcement of positive topline results from its Phase 3 VERITAC-2 clinical trial. Despite meeting its ...

NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 ...